Wednesday, October 02, 2024 2:54:26 PM
$RNAZ I can only make you a millionaire if you listen, and listen closely.
Estrella treated their first patient in phase 1/2 study, just like Transcode. They started 7/31/24. And Transcode around 8/15/24 (give or take).
Again, these studies are reviewing tolerance and toxicity!
HOWEVER, they announced their patient had received a complete response!
What is a complete response? Means no detectible sign or disease or cancer after treatment.
Why is this important for RNAZ?
Their animal trial showed the same!
They didn’t announce anything for phase 0. We are in Phase1/2 and only takes 4 weeks to determine complete response (which is around now), and another 8 weeks to validate toxicity and side effects during/after treatment.
So news can come any day, and I believe the company disclosed to Nasdaq during meeting yesterday. No news releases, why?
Read between the lines!
Tick Tock!!!
https://finance.yahoo.com/news/estrella-immunopharma-achieves-complete-response-160000432.html
Estrella treated their first patient in phase 1/2 study, just like Transcode. They started 7/31/24. And Transcode around 8/15/24 (give or take).
Again, these studies are reviewing tolerance and toxicity!
HOWEVER, they announced their patient had received a complete response!
What is a complete response? Means no detectible sign or disease or cancer after treatment.
Why is this important for RNAZ?
Their animal trial showed the same!
They didn’t announce anything for phase 0. We are in Phase1/2 and only takes 4 weeks to determine complete response (which is around now), and another 8 weeks to validate toxicity and side effects during/after treatment.
So news can come any day, and I believe the company disclosed to Nasdaq during meeting yesterday. No news releases, why?
Read between the lines!
Tick Tock!!!
https://finance.yahoo.com/news/estrella-immunopharma-achieves-complete-response-160000432.html
Recent RNAZ News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/01/2026 12:59:50 PM
- TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer • PR Newswire (US) • 05/27/2026 12:04:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/26/2026 10:46:35 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/26/2026 10:43:50 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 08:15:37 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/20/2026 04:15:17 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/08/2026 09:20:58 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 04/30/2026 09:24:06 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/30/2026 08:15:15 PM
- TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University • PR Newswire (US) • 04/27/2026 12:02:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/15/2026 08:17:42 PM
- TransCode Therapeutics signs financing deal worth up to $20 million • IH Market News • 04/07/2026 01:51:53 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/07/2026 12:37:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 12:35:16 PM
- TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028 • PR Newswire (US) • 04/07/2026 12:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/03/2026 09:06:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:05:39 PM
- TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Pa • PR Newswire (US) • 03/03/2026 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 01:10:39 PM
- TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development • PR Newswire (US) • 02/23/2026 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2026 01:10:42 PM
- TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 • PR Newswire (US) • 02/05/2026 01:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/06/2026 01:04:38 PM
